Introduction
Neurodegenerative diseases are frequently characterized by the aberrant misfolding and aggregation of intrinsically disordered proteins. Pathological proteoforms can variably influence the pathogenesis and progression of different neurodegenerative diseases. Synucleinopathies are amongst the most devastating of age-related neurodegenerative disorders, the most prevalent of which is Parkinson's disease (PD) . Although significant strides have been made in symptomatic treatment for PD patients since the disease was first described over 200 years ago, therapeutics designed to halt progression or modify the course of disease have remained elusive (Obeso et al., 2017) . A central archetype for the pathogenesis of PD and related synucleinopathies, including multiple system atrophy (MSA) and dementia with Lewy Bodies (DLB), postulates that proteopathic aggregation of the protein alpha-synuclein (αS) may have causal association with cellular dysfunction and cell death resulting in clinical signs and symptoms (Wong and Krainc, 2017; Henderson et al., 2019) . Furthermore, a mounting body of evidence suggests that pathologic αS may behave as a prion-like protein and propagate from cell-to-cell via permissive templating. These pathological proteoforms may confer toxicity to naïve recipient cells and trigger the spatiotemporal spread of pathology associated with phenotypic presentation (Chu and Kordower, 2015; Brundin et al., 2016; Ugalde et al., 2016; Chen et al., 2018; Melki, 2018; Steiner et al., 2018; Vargas et al., 2019) . Thus, preventing the aggregation and transmission of toxic αS species with antibody-centric pharmaceuticals is an attractive therapeutic paradigm that may effectively modify the course of disease.
Vaccination and passive immunotherapies have been in continual use to treat disease since their conception in the late 1700s (Plotkin, 2014) . Significant strides in the clinical use of immunotherapy for specialized subsets of cancer and autoimmune disease patients have launched a new wave of development for antibody-based therapies in the last few decades. In particular, clinical efficacy and successful pipeline development of immunotherapeutic drugs for the treatment of multiple sclerosis has sparked hope for potential treatment for neurodegenerative disorders (Baecher-Allan et al., 2018) . Misfolded protein targets are ubiquitous amongst neurodegenerative disorders, making them exciting candidates for immunotherapies designed to engage specific misfolded proteins with high specificity. Furthermore, antibody-based therapies are engineerable constructs with long serum halflives, making them appropriate for age-related diseases that may necessitate elongated dosing regimens.
Immunotherapeutic modalities targeting proteinopathy in neurodegenerative diseases have steadily developed over the past few decades with several active and passive therapies in various stages of preclinical and clinical development. Although the process of bringing PD immunotherapies to clinical trials has trailed that of Alzheimer's https://doi.org/10.1016/j.nbd.2019.104587 Received 11 July 2019; Received in revised form 12 August 2019; Accepted 23 August 2019 disease, several antibody-based treatment strategies based upon αS are currently in various stages of development. Herein, we review the targets and status of immunotherapeutic agents for PD, highlight potential clinical ramifications, and address concerns and roadblocks to viable clinical constructs.
Alpha-synuclein and proteotoxicity in PD
Parkinson's disease pathology is characterized by megadalton, proteinaceous inclusions called Lewy Bodies. Although typified by motor dysfunction caused by nigrostriatal neurodegeneration, PD patients present with several serious non-motor signs and symptoms including neurocognitive deficits, behavioral abnormalities, and autonomic dysfunction. Critical to our understanding of the role of αS in PD, several genetic mutations (A30P, E46K, H50Q, G51D, A53T/E) (Polymeropoulos et al., 1997; Conway et al., 1998; Zarranz et al., 2004; Appel-Cresswell et al., 2013; Lesage et al., 2013; Proukakis et al., 2013; Pasanen et al., 2014) and multiplications (Singleton et al., 2003; Chartier-Harlin et al., 2004; Ibanez et al., 2004) of the SNCA gene encoding for αS protein have been identified, demonstrating that alterations in αS are causative in inherited forms of PD. Furthermore, Spillantini and colleagues identified filamentous αS to be the primary component of Lewy deposition in both cases of idiopathic PD and DLB, suggesting a primary role for the protein in the pathogenic process in all PD cases (Spillantini et al., 1997; Spillantini et al., 1998b) . αS was subsequently identified as the major component in Papp-Lantos bodies, or glial cytoplasmic inclusions (GCIs), found primarily in oligodendrocytes of post-mortem MSA brains (Spillantini et al., 1998a) suggesting that αS is associated with the primary pathology seen in atypical PD as well.
Since then, accumulating evidence has suggested a number of mechanisms through which αS can transmit toxicity to brain-cell populations and can induce or exacerbate pathology in vivo (Wong and Krainc, 2017) . αS is a natively unstructured protein that predominantly resides at synaptic terminals across the neuraxis (Maroteaux et al., 1988; Kahle et al., 2000) . αS has principally been shown to act as a membraneassociated liason/regulator for SNARE complex formation, inter-membrane dynamics, and vesicular fusion (Burre et al., 2010; Benskey et al., 2016; Lou et al., 2017) , however its precise function remains unconfirmed. Misfolded αS can form into beta-sheet aggregate species ( Fig. 1.1 ), driven by hydrogen bonding and steric fitting at the nonamyloid component (NAC) region. Misfolding can be induced by numerous cellular factors or physiological conditions, amongst the most pertinent to PD pathophysiology include: rampant production of reactive oxygen species (Scudamore and Ciossek, 2018) , mitochondrial perturbations (Vicario et al., 2018) , membrane/lipid-interface dynamics with αS (Suzuki et al., 2018) , altered cellular pH (McClendon et al., 2009 ), overexpression of naïve protein (Singleton et al., 2003; Ibanez et al., 2004) , and increased proteostatic burden and inundated/ dysregulated clearance machinery (Wong and Krainc, 2017) . αS protein also is susceptible to site-specific C-terminal truncations by calpain-1, oligopeptidases, cathepsin-D, or incomplete proteolytic digestion, with truncated species featuring a higher capacity for fibrillarization than full-length monomers (McClendon et al., 2009; Games et al., 2014; Sorrentino et al., 2018; van der Wateren et al., 2018; McGlinchey et al., 2019) . Post-translational modifications (PTMs) or metal-binding interactions have also been linked to enhanced seeding and aggregation (Barrett and Timothy Greenamyre, 2015; Gonzalez et al., 2019) . The most commonly associated PTM with pathological αS is phosphorylation events at serine-129 (pS129), although whether these events implement pathology or are protective mechanisms remains heavily debated (Oueslati, 2016) . Several other phosphorylation and nitrosylation sites, predominantly in the C-terminal region, have also been implicated in mediating αS intra-molecular association motifs and signaling sites that may play crucial roles in therapeutic targeting (Barrett and Timothy Greenamyre, 2015; Oueslati, 2016; Stefanis et al., 2019) .
As is the case with prion proteins, αS aggregate seeds can induce the misfolding and aggregation of naïve protein, through a process called permissive templating, rendering αS pathologic species as potentially infectious particles (Chu and Kordower, 2015; Vargas et al., 2019) . As αS particles mature from oligomers to protofibrillar and fibrillar species, cooperative recruitment of monomers (or multimers) accelerates aggregate maturation.
In 2003, Braak and colleagues described the coincidence of PD-related functional deficits with neuropathological progression (Braak et al., 2003) . According to Braak, Lewy pathology may have been triggered from pathology initiated in the peripheral nervous system which would then propagate to and through the central nervous system to brain regions associated with motor and extra-motor PD phenotypic presentations (Braak et al., 2003) . Braak neuropathological staging has since been used to map the progression of pathological correlates for multiple protein-related neurodegenerative disorders, including Alzheimers (tau and A beta) (Braak et al., 2006; Braak et al., 2011) , amyotrophic lateral sclerosis-frontal temporal dementia (TDP-43) (Brettschneider et al., 2013) , and other synucleinopathies. Evidence of theoretical cell-to-cell transfer of αS in clinical PD was further amplified with two independent discoveries of Lewy body formation in engrafted neurons of PD patients that received fetal cell transplants (Kordower et al., 2008; Li et al., 2008) . The formation of Lewy bodies in the grafted cells were directly linked to the age of engraftment (> 10 years) implicating a temporal dependence for aggregation to permit Lewy-body like fibrillar deposition (Chu and Kordower, 2010; Li et al., 2010) . Following these observations, several groups investigated the prion-like quality of αS protein in animal models. αS pre-formed fibrils (PFFs) are capable of seeding endogenous αS protein and propagating pathology when injected into the striatum or olfactory bulb of rodents (Volpicelli-Daley et al., 2011; Rey et al., 2013; Paumier et al., 2015; Rey et al., 2018) . PFF-induced spread of αS can also be enhanced with varying genetic backdrops associated with PD genotypes, such as LRRK2 or Engrailed-1, reinforcing disease relevance (Bieri et al., 2019; Chatterjee et al., 2019) . Similarly, lysates derived from brain tissue of patients exhibiting Lewy pathology or GCIs were also capable of stimulating the intracellular seeding and spread of pathology when injected into animals (Watts et al., 2013; Recasens et al., 2014) . Interestingly, recent studies have shown αS PFFs injected proximal to the myenteric plexus of wild-type mice are capable of triggering neuropathology and resultant parkinsonism/neurocognitive deficits in the brain, supporting Braak's proposed paradigm of peripheral-to-central pathogenesis . Repeated validation of in vivo spread of pathology via these models generated significant interest in mechanisms involved with proteinaceous propagation in neurodegenerative diseases as well as developing methods to thwart this spread for potential clinical translation.
Potential targets for immunotherapeutic intervention in PD
Several studies indicate a significant extracellular pool of αS (El-Agnaf et al., 2003; Paleologou et al., 2009; Tokuda et al., 2010; Shi et al., 2014; Cao et al., 2019; Stefanis et al., 2019) . Although not discussed in detail here, several excellent reviews have summarized the multiple proposed routes of cell-to-cell spread of αS ( Fig. 1.1) Rodriguez et al., 2018; Vasili et al., 2019) . Antibody-based therapies primarily target exposed extracellular species of αS, thus placing significant importance to the mechanisms for αS transmission pertinent to PD patient symptomatology ( Fig. 1.2 ). Immunotherapeutic modalities targeting αS have focused on engagement of pathological aggregate species of αS instead of the monomer. The maturation of αS aggregates will have important implications for disease-relevant targeting, particularly in the absence of adequate biomarkers that identify subjects destined to become parkinsonian prior to the initiation of the synucleinopathy. Additionally, the data for which αS aggregate species is attributed with the highest degree of cytotoxicity is disparate.
Multiple reports have illuminated the predominant toxicity of αS oligomers, particularly in the disruption of lipid membranes, mitochondrial function, and lysosomal efficiency (Bucciantini et al., 2002; Danzer et al., 2007; Winner et al., 2011; Fusco et al., 2017; Wong and Krainc, 2017) . However, others have contended that mature fibrillar forms of αS are the more toxic variant of αS aggregate, with the discrepancies in data potentially due to inequitable comparisons of particle concentrations for a number of studies assessing levels of toxicity (El-Agnaf et al., 1998; Nonaka et al., 2010; Pieri et al., 2012; Bousset et al., 2013; Lashuel et al., 2013; Froula et al., 2019) . There is still uncertainty as to whether Lewy bodies themselves can cause cellular dysfunction, or if Lewy-like deposition occurs in cells in an effort to protect them from cytotoxic αS aggregate pathways. Resolution to these questions may be necessary to facilitate αS target selection for antibody-based therapies.
An alternative route for targeting the propagation of toxic αS species that remains unexplored is the downregulation or interference of the proteopathic-seed uptake mechanisms of recipient cells ( Fig. 1.3) . Several recent studies have highlighted potential mechanistic underpinnings for the selective uptake of toxic variants of αS. The lymphocyte activation gene 3 (LAG3) has been shown to selectively interact with aggregated αS variants compared to monomeric αS in vitro and in vivo (Mao et al., 2016; Wood, 2016) . Two antibodies against LAG3 (C987W and 410C9) effectively inhibited the spread of αS PFFs in cell culture, although whether either antibody could protect against PFF injections in vivo is unknown (Mao et al., 2016) . Recently, αS oligomers have also been shown to directly interact with connexin-32 (CX32) gap junction proteins as a potential pathway for direct cell-to-cell transmission (Reyes et al., 2019) . A pair of cell culture studies showed αS, as well as aggregate forms of tau and Aβ, to interact with specific heparin sulfate proteoglycan cell surface moieties prior to internalization (Holmes et al., 2013; Stopschinski et al., 2018) . Antibodies against membrane-bound or transmembrane proteins that interact with toxic αS species prior to cellular entry may provide longer temporal windows for therapy, as the extracellular latency of αS species is difficult to characterize. However, due to the functional multiplicity of membrane receptors, antibody products raised against these targets may have increased off-target effects by blocking alternative molecules that utilize the same surface receptors for cellular action. Furthermore, mechanistic targeting of αS species uptake may also potentially interfere with intrinsic processes for reducing extracellular αS or induction of inflammatory responses to pathological stimuli, such as glial uptake and activation. Overall, constructs driven toward uptake mechanisms require robust characterization and validation across in vivo αS models Figure 1 . Mechanistic targets of antibody-based therapies for synucleinopathies. 1) Intrinsically disordered monomeric alpha-synuclein misfolds and aggregates to form pathological seeds. Seeds induce misfolding and recruit naïve monomers to elongate and form oligomers and protofibrils. Through various pathways, alpha-synuclein proteoforms are released into the extracellular space where they can propagate to naïve recipient cells or stimulate the activation and recruitment of reactive glial populations. 2) The primary target of immunotherapy drugs is to bind proteopathic, extracellular alpha-synuclein and stimulate clearance through downstream Fcγ effector function, principally through microglial-mediated degradation.
3) Antibodies can also target membrane surface receptors of recipient cells to inhibit the binding and uptake of pathologic alpha-synuclein species. 4) To target intracellular alpha-synuclein deposition and pathology, engineered antibody fragments can hijack cellular uptake machinery for enhanced cellular penetrance. Antibody constructs can also be delivered as transduced genes by viral vectors to constitutively produce and assemble construct peptide sequences. 5) Intrabodies that effectively assemble intracellularly can target multiple motifs to inhibit aggregation paradigms and may employ cellular degradation mechanisms to enhance clearance of proteopathic targets. 6) Antibodies may also target cytokines released from activated microglia or reactive astrocytes to modulate inflammatory pathways that enhance protepathic seeding and release. and evidence of clinical manifestation to establish reliable targets for clinically relevant therapeutic avenues. Additionally, while a majority of immunotherapeutic constructs aim to mitigate extracellular pathology, intracellular αS targeting is still of particular interest due to critical intracellular events that initiate and perpetuate pathology ( Fig. 1.4 ,5). Delivery of intracellular antibodies or antibody fragments (or intrabodies) can be difficult due to size-restrictions of membrane permeability and maintenance of structural and functional viability within cellular environments. However, several elegant methods have been employed to enhance intracellular targeting. Trojan-horse intrabodies are engineered with signaling sequences that employ endocytotic membrane receptors and effectively ferry therapeutic constructs across the blood-brain barrier and into cells . Another mechanism for long-term therapeutic delivery is to utilize viral vectors to transduce genes of intrabody constructs within the cell for constitutive expression (Bhatt et al., 2013; Chatterjee et al., 2018) . Although beneficial for the window of therapeutic delivery, current clinical gene therapy methods are irreversible and require thorough examinations of the safety and tolerability of the transduced material.
Although directly limiting αS proteinopathy is the main target for immunotherapies, modulating immune system reactivity to PD pathophysiology is another avenue of potential antibody-mediated clinical benefit ( Fig. 1.6 ). Several lines of evidence have long shown strong correlation with immune activation and inflammation associated with brain regions susceptible to PD neurodegeneration (Przedborski, 2010; Mosley et al., 2012; Caggiu et al., 2019) . However, it is still unclear whether inflammatory processes in PD are a cause or consequence of pathology. Inflammatory activation, however, has been linked in several instances with accelerated αS propagation, potentially exposing a window for immunotherapeutic intervention to thwart progression of disease. Gordon and colleagues demonstrated the inhibition of the NLRP3 inflammasome in mice inoculated with αS PFFs mediated IL-1β release and decreased the overall pathological burden of αS (Gordon et al., 2018) . Similar studies have linked other activated microglial factors with αS toxicity, specifically toll-like receptors (TLR) and proinflammatory molecules like TNF-α and Nitrous Oxide (Beraud and Maguire-Zeiss, 2012) . Evidence of microglial reactivity preceding proteopathic accumulation of αS in transplanted fetal grafts of PD patients further implicates inflammatory contributions to seeding and transmission of αS pathology (Olanow et al., 2019) . Passive immunotherapeutics against pro-inflammatory cytokines, such as canakinumab (anti-IL-1β) or adalimubam (anti-TNF-α), have been widely used for clinical interventions for auto-immune disorders and may provide a facilitated route for clinical translation for PD patients (Dhimolea, 2010; Beraud and Maguire-Zeiss, 2012; Voet et al., 2019) . Such clinical and commercial success with immunotherapeutic agents for other diseases has attracted significant interest in immunotherapeutic methods to treat clinical PD.
Active immunization
A significant challenge for immunotherapeutic intervention for PD patients is exploiting a therapeutic window that may alter the progression of disease. Vaccination and active antibody therapies that stimulate humoral responses of host organisms have the benefit of providing long-term physiological clearance of target proteins by hijacking host immune machinery without prolonged and repeated dosing. Particularly for proteopathic neurodegenerative insult with unpredictable timelines of pathogenesis, latent protection against protein aggregation is ideal. Furthermore, theoretical prophylactic inoculation prior to the induction of proteinopathy may ultimately be an effective means for protection against neurodegenerative pathogenesis in the long term, but this concept requires known regional pathology in patients with prodromal disease. Efficacious active immunization strategies in PD must overcome two rate-limiting obstacles: 1) reprogram the host immune system's self-tolerance for target antigens (αS) and 2) ensure adequate supply of antibodies across the blood-brain barrier (BBB).
Recently, the Austrian company Affiris completed a series of Phase I clinical trials investigating safety and dosing for two anti-αS vaccines, PD01A and PD03A, or AFFITOPE (Table 1) . Affiris' AFFITOPE vaccines use short peptide fragments that mimic C-terminal residues of αS (110-130) tethered to carrier proteins and administered with an aluminum hydroxide adjuvant to prime host immunity (Mandler et al., 2014) . AFFITOPE vaccines were derived from a set of original preclinical studies from Masliah and colleagues who were the first to test active immunization paradigms for PD animal models (Mandler et al., 2014) . Using two different transgenic mouse models overexpressing αS under the platelet-derived-growth-factor-β (PDGF) promoter and the Thy1 promoter, the selected candidate peptide AFF1 was able to generate high titers of antibodies against aggregated forms of αS which was detectable in CSF, plasma, and brain parenchyma (Mandler et al., 2014) . Immunization decreased αS deposition in both models, reduced striatal degeneration, and rescued spatial memory deficits and motor dysfunction (Mandler et al., 2014) . AFFITOPE vaccines also showed similar protection in transgenic mouse models of MSA (Mandler et al., 2015) . Successful pre-clinical efficacy, as well as established safety and tolerability, led the way for Phase I trials of PD01A and PD03A (Table 1) . In this regard, both vaccines were well tolerated at low and high doses with no reported serious adverse events or serious adverse reactions. Although the clinical study was not powered to appropriately gauge efficacy, PD01A patients showed stabilized clinical scores compared to the placebo group in an open label assessment leading to the design and in initiation of Phase II clinical trials.
Although the vaccines produced by Affiris are the only active constructs to translate to the clinic to date, multiple other peptidic vaccines have shown pre-clinical efficacy in vivo. The earliest study of vaccination against recombinant hαS was performed in PDGF-αS that were immunized with full-length antigen paired with a Freund adjuvant to stimulate immunity against pathological aggregation (Masliah et al., 2005) . The study postulated that immunized animals had significant synaptic preservation due to antibody affinity for membrane-bound aggregate species that were internalized and degraded by lysosomes (Masliah et al., 2005) . These experiments led the way for numerous vaccination approaches that modified similar treatment paradigms to enhance selectivity and targeting. A recent study combined administration of full-length αS with rapamycin geared to elicit a regulatory Tcell response in conjunction with humoral immunity significantly reduced pathological αS deposition and concurrent neurodegeneration in PDGF-αS mice . The administrants were delivered in cell-targeting glucan microparticles with more robust reductions observed in animals treated with both the antigen and rapamycin compared to animals treated with rapamycin or αS alone . Similarly, a vaccination strategy utilizing full-length recombinant αS delivered with a complete Freund adjuvant was able to trigger an adaptive immune response in rats that received nigral lesions of AAV-αS (Sanchez-Guajardo et al., 2013) . Persistent CD4+ cell infiltration and microglial phenoconversion mediated a significant reduction in striatal αS pathology (Sanchez-Guajardo et al., 2013) . Another study delivered C-terminal peptide fragments of αS in RNA-bacteriophage Qbeta virus-like particles to mice overexpressing human αS with a murine SNCA null background (Doucet et al., 2017) . Vaccination with the virus-like particles generated high titers of anti-αS antibodies that could identify Lewy pathology in human post-mortem PD tissue and bound with~100 higher affinity to oligomeric species of αS than monomeric αS (Doucet et al., 2017) . However, immunized animals did not show any functional or pathological benefit from treatment (Doucet et al., 2017) .
Alternative approaches to peptidic vaccine-based immunizations against αS have also shown pre-clinical efficacy. One such approach showed dendritic cells (DC) sensitized to αS peptide fragment epitopes ex vivo were capable of inducing strong antibody responses when delivered intravenously to A53T-hαS transgenic mice compared to cells sensitized to full-length αS (Ugen et al., 2015) . However, both peptidesensitized DCs and full-length sensitized DCs exhibited protective benefit in rotarod latency and IL-1α expression profiles, suggesting mediated DC effector response to both variants (Ugen et al., 2015) . DNAbased vaccinations also provide a route for immunization that may stimulate a stronger effect to total proteinpathy due to the targeting of naïve protein substrates prior to aggregate recruitment. Chen and colleagues developed a nucleic acid vaccine (pVAX1-IL-4/SYN-B) that showed increased antibody titers against αS, functional midbrain dopaminergic neuronal protection, and behavioral improvement in mice lesioned with subacute doses of MPTP (Chen et al., 2013) . However, effects on αS aggregation/target engagement in treated cohorts, or experimentation in αS-based animal models, were not shown. The lack of selectivity for αS conformers known to be pathologic and the risk of over-reduction of functional monomeric αS should be considered moving forward with nucleic acid based active immunization strategies.
Passive immunotherapy
Tremendous strides have been made in the past few decades in the development and engineering of antibody constructs that are generated ex vivo and administered to subjects through passive immunization strategies. Unlike vaccination, passive immunotherapies benefit from epitope selectivity of target antigens. Furthermore, dosing and delivery of passive antibody treatments can be specialized based on the parameters of the target antigen or the antibody construct itself. One drawback is the necessity for repeated dosing, potentially over the course of many years. However, most antibodies utilized for passive immunotherapies are stably bioactive and have relatively long serum half-lives. With consideration of safety and potentially adverse effects, passive dosing strategies also benefit from being reversible.
Unlike the paucity of active immunization constructs that have translated to the clinic in the field of PD, several passive antibody therapies are in various phases of clinical trial. The earliest passive immunotherapy construct, PRX002/RG7935 (Prasinezumab), developed by Prothena and Roche is currently in an active Phase II efficacy trial (Pasadena) and was initiated June 2017 (Table 1) . PRX002 is a humanized construct derived from a monoclonal antibody developed by Masliah and colleagues, 9E4 . The C-terminal targeting 9E4 antibody was selected from a panel of four monoclonal antibodies raised against αS and was delivered intraperitoneally to PDGF-αS transgenic mice weekly for 6 months. 9E4 treated animals showed significant motor improvement (pole test, rotarod) and spatial cognitive protection (water maze) compared to IgG1-treated control animals . Importantly, 9E4 was reported to effectively cross the BBB and demonstrated efficient Fcγ-effector activation of autophagy . The pre-clinical data also suggested dual mechanistic underpinnings of 9E4: 1) shuttling of bound antigen αS to the lysosomal compartments for degradation and 2) interference of calpain-interactive C-terminal cleavage sites that exacerbate aggregate toxicity . Masliah and colleagues also reported two independent antibody constructs, 1H7 and 5C1, that preferentially targeted the C-terminal of αS, prevented calpain-mediated cleavage, and deterred cell-to-cell propagation of aggregate αS species (Games et al., 2014; Spencer et al., 2017) . Pre-clinical evidence of therapeutic efficacy led to the initiation of a Phase I multicenter trial investigating safety and pharmacokinetics of PRX002 in healthy patients ) and a double-blind, placebo-controlled trial for idiopathic PD patients (Jankovic et al., 2018) . In both reports, PRX002 was well tolerated with no serious adverse events or immunogenicity described Jankovic et al., 2018) . Comparative data from patients with idiopathic PD also suggests peripheral evidence of PRX002 target engagement in reductions of unbound serum αS (Jankovic et al., 2018) . The 2-year phase II trial is expected to conclude in 2021.
In January 2018, Biogen initiated a phase II clinical trial (SPARK) investigating safety, pharmacokinetic, and pharmacodynamics of its passive antibody construct, BIIB054 (Table 1 ). BIIB054 is an N-terminal αS targeting monoclonal antibody that was licensed from the biopharmaceutical company, Neurimmune. BIIB054 was developed from human memory B-cell antibody libraries of healthy individuals , similar to screening methods used for selection of passive antibody constructs catered towards Aβ (Sevigny et al., 2016) and SOD1 (Maier et al., 2018) . Pre-clinical data showed BIIB054 to have a robust affinity for aggregated species of αS (~800X greater than the monomer) and effective prevention of αS spread in mice intracerebrally injected with αS PFFs . BIIB054 was also effective in protecting against motor deficit (wire hang test) and maintained striatal dopamine transporter levels . Recently, Biogen reported data from a Phase I safety and pharmacokinetic trial conducted with healthy volunteers and PD patients (Brys et al., 2019) . Adverse events were mild and considered independent of therapeutic action (Brys et al., 2019) . BIIB054 also showed favorable levels of bound serum αS, and a serum half-life of 28-35 days (Brys et al., 2019) . The 2-year Spark trial is expected to conclude in July 2021.
Several additional pharmaceutical companies have initiated Phase I clinical safety and tolerability programs for candidate passive antibody therapies. The Danish company, Lundbeck, began Phase I investigation of Lu AF82422 (Table 1) in July 2018. The Phase I trial aims to investigate safety and tolerability of a single dose of Lu AF82422 in Japanese populations of healthy individuals and PD patients. In October 2017, AstraZeneca, in partnership with Takeda Pharmaceutical Company, launched a Phase I single, ascending dose study of their antibody MEDI-1341 in healthy individuals (Table 1) . MEDI-1341 is a highly selective, C-terminial targeting anti-αS antibody that features reduced Fcγ effector function to avoid robust immune responses and enhance safety and tolerability https://www.astrazeneca.com/media-centre/ press-releases/2017/astrazeneca-and-takeda-establish-collaborationto-develop-and-commercialise-medi1341-for-parkinsons-disease-25082017.html (Schofield et al., 2019) . In a pre-clinical study, an effector-null version of the MEDI-1341 construct was equally effective at reducing the levels of pathological spread in animals injected with lentiviral-αS as its unmodified counterpart (Schofield et al., 2019) . Most recently, BioArctic licensed ABBV-0805 (formerly BAN0805) to Abbvie and initiated a Phase I clinical trial in March 2019. ABBV-0805 was reported to selectively target oligomeric and protofibrillar species of αS and improve lifespan of a PD mouse model. Limited peer-reviewed data is available for the above listed candidate therapeutic antibodies.
Multiple other pre-clinical studies have reported passive immunotherapy constructs that have yet to proceed to clinical entities. Bae, et. al. reported an antibody raised against the C-terminal of αS (antibody 274) to successfully reduce cell-to-cell transfer of αS in PDGF-αS mice (Bae et al., 2012) . Interestingly, the study provides characterization of the antibody-induced microglial-mediated clearance of pathologic aggregate αS species released from neurons (Bae et al., 2012) . Lee and colleagues described two anti-αS antibodies, Syn211 and Syn303, were effective in halting αS PFF entry in neuronal cultures, and could inhibit transcellular spread of αS aggregates (Tran et al., 2014) . Syn303, which is reported to bind to pathological conformations of αS, was also capable of protecting nigrostriatal dopaminergic integrity in mice injected with αS PFFs (Tran et al., 2014) .
A significant consideration for anti-αS immunotherapeutic drugs is the degree of aggregate maturity, i.e. which proteoforms are present in patients. Whereas most of the aforementioned therapeutics target αS aggregates, patients with advanced PD (in whom pathology has likely persisted for years) may not feature a large, accessible load of early αS proteoforms to experience the clinical benefits of the therapy. Furthermore, the antibody affinity and avidity measurements may not stay consistent as fibrillar antigen species mature. Several groups have developed antibodies that specifically target advanced oligomeric, protofibrillar, and fibrillar forms of αS aggregates. Lindstrom, et. al. reported the protofibril selective antibody mAb47 was efficacious in the reduction of both soluble and membrane-associate αS protofibrils and improvement in motor symptoms when administered weekly to Thy1-hA30P-αS transgenic mice (Lindstrom et al., 2014) . Another study compared the differential effects of immunotherapy antibodies targeting various oligomeric and fibrillar strains of αS in Thy1-αS transgenic mice, validating enhanced function of antibodies targeting aggregate species, but showing mixed results in which target may be more effective in reducing overall pathology (El-Agnaf et al., 2017) .
Exploiting a novel paradigm independent of direct targeting of αS, Masliah and colleagues recently reported pre-clinical efficacy of a monoclonal antibody targeting TLR-2 in mediating synucleinopathy . Using PDGF-αS transgenic mice, anti-TLR2 antibody therapy was neuroprotective and decreased the neuronal and astroglial accumulation of αS deposits, citing NFκB dependent pro-inflammatory mitigation downstream of TLR-2 inhibition . Several other potential levels of inflammatory control and immune mediation of PD proteinopathy may also be worthy targets of immunotherapeutic intervention (Fig. 1.6 ).
Intrabodies and targeting intracellular proteinopathy
Although anti-αS antibodies have shown promising in vivo benefit against proteinopathy in animal models, synucleinopathic seeding initiates as a stochastic intracellular event and depends on lag phase aggregation prior to the generation of fibrillar species capable of propagating pathology. Furthermore, whether αS species truly transfer from cell-to-cell in clinical PD is unconfirmed. Thus, engaging intracellular αS species is an attractive target mechanism for interference of aggregate formation or reducing the level of seeds or substrate for fibrillarization. Intrabodies derived from antibody fragments, including single-chain antibodies (ScFV) and single-domain nanobodies, are small 14-30 kDA proteins that can be easily engineered and benefit from enhanced physiological penetrance.
We have recently demonstrated that two nanobody constructs, VH14 (human) and NbSyn87 (camelid), alleviate pathology when delivered as genes by adeno-associated viruses (AAV) to an AAV-αS rodent model of synucleinopathy (Chatterjee et al., 2018) . Both nanobodies were engineered with a proteasome-targeting "PEST" motif to enhance overall construct solubility and to promote clearance of target antigens via proteasomal degradation (Joshi et al., 2012; Butler et al., 2016) . When administered as gene therapy agents in vivo, both nanobodies reduced pS129 deposition, although the NAC-core targeting VH14*PEST intrabody provided better protection from nigrostriatal insult (Chatterjee et al., 2018) . Using a similar antibody engineering concept, Masliah and colleagues tethered the LDL-receptor binding site of apolipoprotein A (ApoB) to D5, a ScFV previously shown to have targeted oligomeric species of αS . The ApoB addon enhanced intracellular penetration via endosomal uptake and promoted the clearance of bound target αS species through late-endosomal/lysosomal degradation . Lentiviral treatment with the engineered D5 ScFV provided both functional and structural neuroprotection in PDGF-αS mice .
To date, multiple libraries of misfolded protein-targeting intrabodies derived from antibody fragments have been screened and validated in various models of neurodegeneration (Reviewed: (Bhatt et al., 2013) and in a counterpart review in this issue by Messer and colleagues). It is still unresolved whether traditional vaccination or passive immunotherapeutics are proficient in inducing cellular immunity or exerting effects intracellularly. Masliah and colleagues speculated the mechanism of active immunization with full-length αS could involve receptor-mediated endocytosis of anti-αS antibodies that could potentially target intracellular species for lysosomal degradation (Masliah et al., 2005) . Strategies independent of antibody-based therapeutics may also facilitate intracellular immunity against toxic αS aggregation. In particular, immunomodulatory paradigms enhancing lysosomal function have shown significant benefit in pre-clinical models of PD. Lysosomal dysfunction has long been linked with dysregulated protein clearance and proteinopathies. Furthermore, the high frequency of genetic mutations for glucocerebrosidase (GBA1) in PD patients has strengthened the link between lysosomal damage and PD pathophysiology (Moors et al., 2017) . Immunomodulatory drugs targeting macroautophagic mechanisms, such as Rapamycin, have shown promising results in αS-centric PD models, but incorporate risks of altering innate, global proteostasis that may cause off-target systemic disruption (Moors et al., 2017) . Overall, significant progress has been made in the advancement of candidate antibodies that may relieve the proteopathic burden of αS in clinical PD. However, several questions must be answered in order to appropriately litigate the effectiveness of antibody-based therapies in the PD clinic.
Lessons from Alzheimer's disease immunotherapy trials
Recent high-profile failures of immunotherapy trials for AD patients have led to rising concerns regarding anti-aggregate targeting across the neurodegenerative disease spectrum. The most notable of which was a recent phase 3 withdrawal of Biogen's Aducanumab, an anti-Aβ passive antibody therapy derived from B-cell populations of control patients without amyloid burden (Selkoe, 2019) . Clinical administration of Aducanumab to AD patients was able to decrease amyloid pathology in dose-dependent fashion and slow the progression of cognitive decline in a double-blind, placebo-controlled phase 1b randomized trial (Sevigny et al., 2016; Budd Haeberlein et al., 2017) . However, Biogen and third-party evaluators designated ongoing results in cognitive protection of the phase 3 trial insufficient for continuation and completion (Selkoe, 2019) . Immunotherapeutic interventions for AD have previously featured successful target engagement but inadequate functional efficacy and cognitive rescue (Wang et al., 2017) . One potential explanation for the lack of clinical efficacy is improper targeting of Aβ as the driver, or even a central contributor, of AD pathogenesis. Opponents of the amyloid hypothesis have long argued that the burden of pathological tau, and neurofibrillary tangles, shows stronger correlation with cognitive deficit and neurodegeneration (Johnson et al., 2016) . Recently, post-mortem analysis of the first AD patients to receive the anti-Aβ active immunotherapy, AN1792, revealed long-lasting protection from Aβ plaque burden; however, patient brains also displayed significant levels of hyperphosphorylated-tau deposition, indicating sustained neuropathological aggregation even with effective therapeutic target engagement (Nicoll et al., 2019) .
Although several anti-tau immunotherapeutic drugs are in clinical development (Hoskin et al., 2019) , a chief concern moving forward is the assumption of mutual exclusivity with proteopathic molecular events. In a study conducted by Lee and colleagues, lysates of AD patient brains rich in neurofibrillary tangles that were injected into mice with significant plaque burden rapidly formed neuropathological tau correlates similar to those observed in clinical AD (He et al., 2018) . These data suggest Aβ-driven proteostatic distress can promulgate cellular conditions permissive for coexistent tau pathology (He et al., 2018) . A recent longitudinal study reported ranked temporal incidence of Aβ and tau pathology with respect to cognitive decline, further corroborating sequential events of proteopathic drivers of disease (Hanseeuw et al., 2019) . Like most neurodegenerative diseases, synucleinopathies often present with concomitant pathologies (e.g. Aβ, tau, TDP-43) that may be essential contributors to disease pathogenesis (Moussaud et al., 2014; Irwin et al., 2017; Irwin and Hurtig, 2018; Robinson et al., 2018) . Although αS is widely considered the primary driver of proteinaceous pathophysiology in PD, dynamic interplay of between αS and other proteopathic molecules may not be adequately alleviated with αS-specific immunotherapy. Thus, cocktail immunotherapies may yield the necessary therapeutic avenue to disrupt widespread proteopathic toxicity effectively. Patients with αS pathology can present Aβ and tau copathologies in over 80% and 50% of cases, respectively (Irwin et al., 2017) . Potential combinatorial therapies may feature dual immunotherapy constructs targeting multiple proteins to reduce overall proteostatic burden and minimize reciprocity between toxic aggregate species. In a study conducted by Rissman and colleagues, dual AFFITOPE vaccination against Aβ and αS provided additive protection in bi-transgenic animals with both Lewy pathology and plaque burden when compared to monovalent immunization (Mandler et al., 2019) . Evidence has also shown that monotherapeutic relief of non-αS proteinopathy may be enough to thwart Lewy pathology. A53T-hαS mice treated with a monoclonal antibody raised against oligomeric tau showed reductions in insoluble αS aggregates and synaptic preservation (Gerson et al., 2018) . These data may justify the repurposing of potentially successful anti-tau therapeutics for use in patients with PD and DLB. Given the temporal coupling of inflammation and proteinopathy in patients with PD, another useful therapeutic paradigm may exist in the pairing of anti-inflammatory/immunomodulatory therapy (such as anti-TLR2 immunotherapy, as previously described) with anti-αS immunotherapeutics. Although testing of combined therapies is feasible with animal models featuring multiple induced pathologies, clinical approval for such approaches will require robust safety and efficacy data and may only be possible with stronger foundations in monitoring pathological progression.
Another common post-hoc explanation for clinical failures for AD is the timing of intervention with respect to the moving target of protein aggregation and propagation. If Aβ pathology does, in fact, promote partner molecular proteinopathies, administering immunotherapeutic intervention to patients already featuring considerable plaque burden may be ineffective in alleviating downstream, or overall, pathology. In the case of Aducanumab, as well as several other recent monoclonal antibodies targeting Aβ, clinical inclusion criteria required patients to have a positive amyloid PET scan-thus potentially incorporating the risk of pre-initiated concomitant pathologies that are not mutual targets of therapy. Furthermore, if Aβ pathology was a significant causal agent in AD pathogenesis, patients with positive PET signals may have protein deposition past a critical threshold to accommodate therapeutic intervention. Similar scrutiny should be levied onto anti-αS immunotherapeutic modalities, as pre-clinical experimentation has not revealed the highly coveted temporal window for appropriate and effectual therapeutic intervention.
Limitations and concerns for αS immunotherapeutic strategies
Although the Alzheimer's field has endured repeated failures with immunotherapeutic efforts against Aβ, antibody-based therapies still may be a therapeutic nexus for the treatment of synucleinopathies. Preclinical models have repeatedly shown αS to have a considerable propensity for prion-like behavior, even in comparison to other amyloidogenic proteins. Additionally, clinical disparities between PD/DLB and MSA lend weight to the notion of differential proteotoxicity with respect to the nature of protein aggregation and the population of toxic assemblies. Though clinical immunotherapy modalities for Parkinson's show intriguing potential, there are a number of limitations and concerns that must be addressed to optimize pipeline development of immunotherapeutic drugs and potentially evade the pitfalls of AD clinical trials.
The most critical roadblock for αS immunotherapy drugs is the lack of reliable markers to evaluate the αS proteopathic burden in patients and assess the stage of αS-mediated pathology. To this date, there is minimal direct evidence of progressive spreading of spatiotemporal αS in clinical PD. Furthermore, the relative contribution of potential propagative seeds to disease progression is currently unknown. Unlike PET imaging of amyloid beta and tau, methods for clinical imaging of synucleinopathy have not yielded clinically relevant entities, although several have shown potential relevance (Catafau and Bullich, 2017; Verdurand et al., 2018) . Non-invasive imaging modalities, such as αS PET tracers, may be integral for successful monitoring of αS disease state as well as potential target engagement for anti-αS clinical modalities. However, to address questions relevant to therapy, viable clinical imaging platforms will require thorough validation of outputs and their correlation to the extent of proteinopathy, i.e. which proteoforms are present in patients, and will readouts effectively gauge if the therapeutic is halting or reversing disease-relevant pathology? Also, it will be important to discern nervous system target selectivity from peripheral target engagement due to ubiquitous αS expression throughout the body. Alternatively, the development of PET ligands targeting microglia and activated forms of CNS glial populations is an intriguing imaging method pertinent to disease progression. As previously mentioned, sitespecific glial activation has been shown to be a strong correlate of PD symptomatology and an indicator (or promoter) of Lewy pathology (Ouchi et al., 2005; Olanow et al., 2019) . Promisingly, the use of an in vivo microglial activation PET ligand, 11 C-PK11195, has shown significant association in patients diagnosed with rapid-eye-movement sleep behavior disorder (RBD), one of the most common prodromal predictors for PD (Stokholm et al., 2017) . These findings suggest in vivo microglial imaging may be an appropriate readout to monitor comprehensive aspects of disease, including state of protienopathy. However, non-specific interactions of microglial PET tracers should be carefully considered if used as markers to monitor spatiotemporal therapeutic efficacy of αS antibody-based agents. Current imaging modalities for αS burden in patients may not have the resolution necessary to extrapolate clinical successes.
Additionally, serum or CSF markers for αS, although promising with advances in αS antibody technology, currently have marginal clinical validation and may not provide widespread relevance to all PD populations. This gap places tremendous burden on establishing appropriate clinical outcome measures to evaluate efficient target engagement. Standard clinical outcome scores for PD patients, such as the Unified Parkinson's Disease Rating Scale or striatal binding ratios with DATscan, may not provide the level of resolution necessary to evaluate effective αS treatment adequately. Furthermore, this disallows appropriate selection criteria for ideal candidates for αS-targeting immunotherapy, as factions of PD patients do not present with Lewy pathology or may have αS pathological scores too advanced for diseasemodifying intervention.
Another primary concern for passive antibody therapies is the strain specificity for the conformer of pathological αS targeted. Several investigations have shown heterogeneous strain specificities of αS aggregate species, and resultant disparities in strain-induced cytotoxicity Peelaerts et al., 2015; Ma et al., 2016; Fusco et al., 2017; Melki, 2018; Karpowicz et al., 2019; Tanaka et al., 2019; Yamasaki et al., 2019) . Biostructural examinations of fibrils born from different variants of αS (mutated, truncated, etc.) or host-cell sources of αS (neuronal/oligodendroglial) reveal significant ultrastructural differences in αS aggregate polymorphs, reinforcing potential target heterogeneity Rodriguez et al., 2015; Guerrero-Ferreira et al., 2018; Li et al., 2018) . Although a majority of passive antibody constructs previously mentioned have shown significantly higher affinity towards aggregate species of alpha-synuclein, evidence of strain specificity is mostly absent and is typically only shown from pathological decreases given the context of the in vivo model in use. However, clearance of some oligomeric species may not comprehensively alleviate disease-relevant pathological conformers, particularly ones applicable to clinical manifestations of synucleinopathy. Standard practice for immunotherapeutic candidate drugs should generally test multiple models of synucleinopathy to validate target engagement across assembly conformations or aggregation paradigms. Similarly, variable aggregation motifs across the spectrum of αS modifications should be considered to validate target engagement, as mutation-driven heterogeneity in αS assemblies may manifest differently with respect to clinical outcomes. An exciting frontier that may address the need for reproducible biomarkers, as well as provide potentials readouts for the context of αS aggregation dynamics, is the use of protein amplification assays to identify misfolded protein aggregates. The advent and use of Protein-Misfolding Cyclic Amplification (PMCA) and Real-Time Quaking-Induced Conversion (RT-QuIC), although clinically nascent, has shown high selectivity and specificity in identifying synucleinopathic burden in prodromal and clinical PD patients (Jung et al., 2017; Paciotti et al., 2018) . αS amplification assays have demonstrated success in the identifying PD patient populations from control subjects using both tissue biopsies and CSF samples (Shahnawaz et al., 2017; Paciotti et al., 2018; Concha-Marambio et al., 2019; Fenyi et al., 2019) . PMCA assays for αS conformers have also shown sensitivity for fixed material, expanding potential use to patient-derived materials previously limited by tissue sampling and processing protocols (Becker et al., 2018) . Validation of amplification assays for use to determine immunotherapeutic efficacy would provide an ideal readout for selective target engagement and correlational pharamacodynamics. Perhaps more importantly, proper clinical characterization of synucleinopathic subtype may allow for patient stratification and selection for candidates most likely to benefit from a particular immunotherapy.
Finally, it will be important to determine what percentage of αS that is transferred extracellularly would be exposed to antibody-based interventions, particularly with respect to clinical synucleinopathies. αS has been mechanistically shown to propagate via tunneling nanotubes, exosomes, or accompanied with molecular chaperones, all of which may protect relevant target epitopes from antibodies in the extracellular space. Until the clinical reality of extracellular αS is better understood, emphasis must also be placed on the pre-clinical investigation of targeting intracellular αS deposition and the role it may play on alleviating neuronal dysfunction. For all current and future clinical investigations, careful curating of patient selection and outcome criteria, as well as direct probing of pharmacodynamics, is essential for appropriate evaluation of immunotherapeutic efficacy for PD.
Conclusions and future directions
The multiple immunotherapeutic agents that are currently in clinical trial for PD have generated renewed excitement about the potential for disease-modification. Furthermore, several innovative techniques in the engineering and development of antibody-based entities have provided a steady supply of on-deck constructs that may eventually reach the clinic. However, many of these efforts may be in vain due to the fundamental lack of characterization of proteinopathy in patients and its relevance to disease progression and pathophysiology. Although models of PD have been extremely useful tools for generating candidate antibody-based drugs, emphasis should be placed on evaluating the direct translation of these models to human disease and how that may affect the success of immunotherapies in the clinic. Additionally, developing suitable methods to appropriately track and characterize disease progression, particularly with respect to αS pathology, is requisite to fairly resolve the clinical potency of antibody-based therapies. Nonetheless, immunotherapeutic intervention for PD and related synucleinopathies is an exciting avenue and may provide the groundwork for analogous therapeutic paradigms across neurodegenerative diseases.
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